Promega Introduces New Mass Spec Reagents, IdeS Protease and Human and Yeast Protein Extracts
Promega Corporation announces the launch of new products for scientists working with mass spectrometry. The IdeS Protease enables fast, easy, high performance digestion of immunoglobulin, while the Human and Yeast Protein Extracts provide a test material for optimizing mass spec sample preparation. The new products add to the company’s existing range of proteases and services to improve mass spec sample prep workflows.
IdeS Protease is a recombinant, engineered version of the immunoglobulin-degrading enzyme from Streptococcus pyogenes. It is a highly specific protease that slices Immunoglobulin G (IgG) at a single, targeted site, offering 100% digestion in 30 minutes with no optimization. IdeS can be used to characterize therapeutic antibody candidates using LC/MS, and contains a histidine tag for easy removal. The versatile Promega IdeS enzyme cuts IgGs from a range of species, as well as Fc-fusion proteins.
The new yeast and human protein extracts are designed specifically for mass spectrometry applications. Available in either predigested, cleaned form for immediate use in LC/MS analysis or intact, undigested form to provide a test material for optimizing mass spec protein sample preparation, the extracts provide clean, consistent, quantified, model system samples for LC/MS method development and instrument monitoring. The yeast extracts are beneficial for users who prefer working with a relatively compact and well-studied proteome, whereas the human extract, with large dynamic range, provides the opportunity to work with complex proteomes. The new products are: MS Compatible Yeast Protein Extract, Digest; MS Compatible Human Protein Extract, Digest; MS Compatible Yeast Protein Extract, Intact; and MS Compatible Human Protein Extract, Intact.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance